

# Lupin marks GLP-1 foray with launch of Liraglutide generic in US

Notably, the type 2 diabetes formulation is likely to be followed by a weight-loss indication product (Saxenda copy). However for India, investors are keenly tracking the company's movement into the semaglutide space which is set to open in March 2026.



Mumbai: Marking its GLP-1 debut, Lupin Limited has announced the launch of its Liraglutide generic 18 mg/3 mL single-patient use prefilled pen in the US.

The Mumbai-based drugmaker's GLP-1

formulation is bioequivalent to Danish drug giant 'Victoza,' indicated as an adjunct to improve glycemic control in patients with type 2 diabetes mellitus.

Notably, the type 2 diabetes formulation is likely to be followed by a weight-loss indication product (Saxenda copy). However for India, investors are keenly tracking the company's movement into the semaglutide space (another GLP-1 blockbuster) which is set to loss exclusivity in March 2026.

At the company's last earnings call (Q1 FY26) the company CEO Vinita Gupta said that, "GLP-1 is going to be our core part of India strategy" and the launch of semaglutide generic injectable is planned in the first wave of generics through partnership"

Meanwhile with the Liraglutide formulation the drugmaker is looking to expand its complex generic base across key markets, including the US which drives a third of its total revenues.

Commenting on the launch, Spiro Gavaris, President – US Generics, Lupin, said, “This marks a significant milestone in enhancing our portfolio of complex injectables and highlights our continued commitment to making essential therapies more accessible for patients.”

According to IQVIA estimates as of August 2025, the Liraglutide type-2 diabetes formulation had estimated annual sales of \$350 million (~Rs 3000 crore) in the US.

**News Source:**

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/lupin-marks-glp-1-foray-with-launch-of-liraglutide-generic-in-us/124301082>